(R)-2-(4-chlorophenyl)-5-(6-(3-(dimethylamino)pyrrolidin-1-yl)pyridin-3-yl)-4H-thieno[3,2-c]pyrrol-6(5H)-one | 1221183-32-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡咯
• 英文名称: (R)-2-(4-chlorophenyl)-5-(6-(3-(dimethylamino)pyrrolidin-1-yl)pyridin-3-yl)-4H-thieno[3,2-c]pyrrol-6(5H)-one
• 英文别名: 2-(4-chlorophenyl)-5-[6-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]pyridin-3-yl]-4H-thieno[2,3-c]pyrrol-6-one
• CAS: 1221183-32-9
• 化学式: C₂₃H₂₃ClN₄OS
• 分子量: 438.981
• InChiKey: CKTBYJIFDWCASF-LJQANCHMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEUR D'HORMONE CONCENTRANT LA MÉLANINE 1 DE TYPE PYRROLONE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010042674A1

  公开（公告）日：2010-04-15

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, Formula Ia, R4, R5, Formula Ib, R3, R3a, W, D, R2a, R2b and R2c are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression, anxiety or intestinal inflammation, by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药用可接受形式，其中R1、公式Ia、R4、R5、公式Ib、R3、R3a、W、D、R2a、R2b和R2c在此处定义。此外，本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖、糖尿病、抑郁症、焦虑或肠道炎症，通过给予根据公式I的化合物的治疗有效剂量。
• PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
  申请人：Zhao Guohua

  公开号：US20110195986A1

  公开（公告）日：2011-08-11

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 4 , R 5 , R 3 , R 3a , W, D, R 2a , R 2b and R 2c are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression, anxiety or intestinal inflammation, by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了按照式I定义的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式，其中R1、R4、R5、R3、R3a、W、D、R2a、R2b和R2c在此定义。此外，本申请提供了含有至少一种式I化合物和可选的至少一种额外治疗剂的制药组合物。最后，本申请提供了通过给予式I化合物的治疗有效剂量来治疗患有MCHR-1调节性疾病或失调的患者的方法，例如肥胖症、糖尿病、抑郁症、焦虑症或肠道炎症。
• US8344160B2
  申请人：——

  公开号：US8344160B2

  公开（公告）日：2013-01-01